Bellerophon Therapeutics Top Insiders
Bellerophon Therapeutics employs about 18 people. The company is managed by 3 executives with a total tenure of roughly 42 years, averaging almost 14.0 years of service per executive, having 6.0 employees per reported executive. Assessment of Bellerophon Therapeutics' management performance can provide insight into the firm performance.
| Peter Pharm Insider Safety Regulatory |
| Parag Shah Insider VP Operations |
Bellerophon |
Bellerophon Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.6034) % which means that it has lost $0.6034 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3854) %, meaning that it created substantial loss on money invested by shareholders. Bellerophon Therapeutics' management efficiency ratios could be used to measure how well Bellerophon Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Bellerophon Therapeutics Workforce Comparison
Bellerophon Therapeutics is rated second in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 145. Bellerophon Therapeutics retains roughly 18.0 in number of employees claiming about 12% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.2) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.48. Bellerophon Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bellerophon Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bellerophon Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bellerophon Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Parag Shah over a year ago Acquisition by Parag Shah of 50000 shares of Bellerophon Therapeutics subject to Rule 16b-3 | ||
Parag Shah over a year ago Acquisition by Parag Shah of 50000 shares of Bellerophon Therapeutics subject to Rule 16b-3 |
Bellerophon Therapeutics Notable Stakeholders
A Bellerophon Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bellerophon Therapeutics often face trade-offs trying to please all of them. Bellerophon Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bellerophon Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Peter Pharm | Safety Regulatory | Profile | |
| Parag Shah | VP Operations | Profile | |
| Nicholas Laccona | Principal Sec | Profile |
Bellerophon Therapeutics Workforce Analysis
Traditionally, organizations such as Bellerophon Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bellerophon Therapeutics within its industry.Bellerophon Therapeutics Manpower Efficiency
Return on Bellerophon Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 6.6M | |
| Working Capital Per Employee | 120.1K | |
| Working Capital Per Executive | 720.7K |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |